QSAM Biosciences Debt/Equity
What is the Debt/Equity of QSAM Biosciences?
The Debt/Equity of QSAM Biosciences, Inc. is -3.34
What is the definition of Debt/Equity?
Debt to equity ratio is a financial ratio indicating the relative proportion of shareholders’ equity and debt used to finance a company’s assets.
lfy (last fiscal year)
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt/Equity of companies in the Health Care sector on OTC compared to QSAM Biosciences
What does QSAM Biosciences do?
QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.
Companies with debt/equity similar to QSAM Biosciences
- Nagarjuna Fertilizers and Chemicals has Debt/Equity of -3.35
- Bunker Hill Mining has Debt/Equity of -3.35
- Choom has Debt/Equity of -3.35
- Ascena Retail has Debt/Equity of -3.35
- Odyssey Marine Exploration has Debt/Equity of -3.35
- Lithium & Boron Technology has Debt/Equity of -3.34
- QSAM Biosciences has Debt/Equity of -3.34
- Surgalign has Debt/Equity of -3.34
- TOM has Debt/Equity of -3.33
- Emerge Commerce has Debt/Equity of -3.33
- Pioneer Distilleries has Debt/Equity of -3.32
- Teles Ag Inform.Tech.Konv has Debt/Equity of -3.32
- PTC Therapeutics Inc has Debt/Equity of -3.32